Stool Collection for Model

NCT06988514 | Completed

• 1 other identifier: 24REX0077603
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

Purpose of this study is to collect stool samples from healthy volunteers

Conditions

A03 - Digestive System; 03 - Bacteria

Keywords

Stool; Microbiota; In vitro

Outcome Measures

Primary Outcomes (1)

• Collect enough acceptable stool samples

  After 14 days of refrain period

Other Outcomes (2)

• The objective of this study is to collect enough acceptable stool samples from healthy participants to develop the three Danone research applications.

  After 14 days of refrain period

• Dietary intakes of the previous day of the faecal samples collection for V2 (collected using my Food24 after sample delivery) and V3 (if applicable).

  After 14 days of refrain period

Study Arms (1)

Healthy volunteer collecting stool samples

EXPERIMENTAL

Healthy volunteer collecting and bringing their stool samples to the investigational site.

Other: Standardized stool collection from healthy volunteers

Interventions

Standardized stool collection from healthy volunteers OTHER

The only interventions are clinical examination, dietary restrictions and samples collection (stool, and urine for the pregnancy tests (when applicable).

Healthy volunteer collecting stool samples

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female participants aged between 18-60 years.
• ≤ BMI \< 30 kg/m2.
• Overtly healthy as determined by the Investigator.
• Regular bowel movements and a mean stool consistency of 3-5 in Bristol Stool Form Scale (BSFS) during the past week.
• Able to:
• Collect their stool samples and delivered at site.
• Speak and read in French.
• Comply with the study protocol and to commit to the instructions and restrictions.
• Refrain from any fermented dairy products throughout the study conduct.
• Refrain from prebiotic, probiotic or synbiotic supplements during the study.
• Maintain the dose of other consumed supplements during the study.
• Limit alcohol consumption to ≤ 2 units (i.e., standard glasses) of alcohol per day with a maximum of 10 units per week during the study.
• Not change substantially their smoking habits during the study.
• Written informed consent Form (ICF) signed by the participant.
• No substantial changes in diet and/or physical activity and/or lifestyle habits, defined as start or stop new foods and/or supplements and/or sports and/or daily habits (i.e., travel, sleeping habits) during the study.

You may not qualify if:

• Any ongoing metabolic disease, inflammatory disease, hepato-gastrointestinal dis-ease or complications, psychiatric or neurological disorder or other diagnosed by a physician.
• Any invasive diagnostic and/or therapeutic procedure related to digestion within the past 4 weeks or plan for a digestive surgery during the study, including dental sur-gery, (i.e., from the onset of the wash-out period to the last data collection).
• General anesthesia during the past 4 weeks or planned during the course of the study.
• For women in childbearing potential, pregnancy or breastfeeding or plan for preg-nancy during the study.
• Use of medication that affects the gastrointestinal (GI) function or use of stomach medication within the past 4 weeks or plan to use of any of these during the study.
• Non-incidental use of \> 4 paracetamol tablets (500 mg), nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin ≤ 2 weeks before the screening visit (V1) or plan of use during the study (if needed, incidental use of ≤ 4 tablets of paracetamol, NSAIDs or aspirin per 2-week period (i.e. ≤ 4 tablets during the refrain period, ≤ 4 tab-lets during the study).
• Antibiotic, antifungal, antiviral or antiparasitic medication within the past 6 months.
• Use of any soft drugs, cannabidiol (CBD), plants medicines and/or hard drugs during the study.
• Participant of another study with investigational or marketed products which could the gut microbiota within the past 4 weeks or plan to participate in such a study dur-ing the study.
• Participant under guardianship, curatorship, person under judicial protection, family empowerment or future protection mandate.
• Employees and/or children/family members or relatives of employees of Danone or the participating sites such as medical, pharmacy, dental and nursing students, sub-ordinate hospital and laboratory personnel, employees of the Investigator or of the Sponsor, members of the armed forces, and persons kept in detention.
• Having received, during the last 12 months, indemnities for participation into clinical study exceeding the annual threshold of 6000€ (including participation to this study).

Sponsors & Collaborators

• Danone Global Research & Innovation Center: lead

Study Sites (1)

CEN Experimental

Dijon, 21000, France

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 16, 2025
• First Posted: May 25, 2025
• Study Start: June 19, 2025
• Primary Completion: November 20, 2025
• Study Completion: December 23, 2025
• Last Updated: January 6, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)